Merck 1Q Revenues: $9.4 billion (+1%) 1Q Earnings: $1.6 billion (+38%) Comments: Pharmaceutical sales were up 1% to $8.2 billion, driven by oncology, hepatitis C and vaccines, largely offset by the loss of market exclusivity for ZETIA, CUBICIN, and NASONEX, as well as ongoing biosimilar competition in Europe for REMICADE. Sales of these products declined $686 million during 1Q17. Sales in the diabetes franchise were also down, reflecting a decrease in JANUVIA and JANUMET due to the timi...